The effect of passages during Japanese BCG vaccine production on genetic stability and protective efficacy

Many genetic differences have been found among currently available BCG vaccines. To avoid continued accumulation of phenotypic or genotypic changes in the strains, WHO and most national regulatory authorities request that the vaccine should not be prepared by more than 12 passages from the master seed lot. However, it has recently been reported that genetic changes occur even during the passage for vaccine production. In this study, the genetic stability of Japanese BCG vaccine production using currently available PCR methods and protective efficacy using a guinea-pig model during the passages were examined. The results showed that there were no significant differences between the seed lot, the product manufactured by normal procedures, and the 20th passage product. These results indicate that the maximum number of passages as currently required by WHO for BCG vaccine production is adequate for the Japanese vaccine, and that new genetic tools may help to examine the quality control of the BCG vaccine.

► Genetic changes are occurred even during the vaccine production within 12 passages.
► We examined genetic stability using currently available PCR methods.
► Protective efficacy is examined using a guinea-pig model during the passage.
► Japanese product is genetically and biologically stable even after 20 passages.